HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
Charles M. Perou(University of North Carolina at Chapel Hill), Ana Vivancos(Vall d'Hebron Institute of Oncology), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), P. Blasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), M.V Dieci, CA Giorgi(University of Padua), Patricia Galván(Vall d'Hebron Institute of Oncology), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Patricia Villagrasa, O. Castillo, Gaia Griguolo(University of North Carolina at Chapel Hill), Mercedes Marín‐Aguilera(Oryzon Genomics (Spain)), J.S Parker(University of North Carolina at Chapel Hill), M. Bottosso, A Prat, Federica Miglietta(University of Padua)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k